BiomXPHGE
About: BiomX Inc is a clinical-stage microbiome company based in Israel. The company is engaged in developing both natural and engineered phage cocktails designed to target and destroy harmful bacteria that affect the appearance of the skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF.
Employees: 71
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
100% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 4
36% more funds holding
Funds holding: 11 [Q2] → 15 (+4) [Q3]
18% more capital invested
Capital invested by funds: $7.81M [Q2] → $9.24M (+$1.42M) [Q3]
17.29% more ownership
Funds ownership: 33.3% [Q2] → 50.59% (+17.29%) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 7
Research analyst outlook
We haven’t received any recent analyst ratings for PHGE.
Financial journalist opinion
Based on 3 articles about PHGE published over the past 30 days
